[go: up one dir, main page]

WO2006010070A3 - Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie - Google Patents

Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie Download PDF

Info

Publication number
WO2006010070A3
WO2006010070A3 PCT/US2005/024414 US2005024414W WO2006010070A3 WO 2006010070 A3 WO2006010070 A3 WO 2006010070A3 US 2005024414 W US2005024414 W US 2005024414W WO 2006010070 A3 WO2006010070 A3 WO 2006010070A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia cells
targeting peptides
compositions
peptides
leukemia
Prior art date
Application number
PCT/US2005/024414
Other languages
English (en)
Other versions
WO2006010070A2 (fr
Inventor
Diana Jaalouk
Wadih Arap
Renata Pasqualini
Original Assignee
Univ Texas
Diana Jaalouk
Wadih Arap
Renata Pasqualini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Diana Jaalouk, Wadih Arap, Renata Pasqualini filed Critical Univ Texas
Publication of WO2006010070A2 publication Critical patent/WO2006010070A2/fr
Publication of WO2006010070A3 publication Critical patent/WO2006010070A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés et compositions supplémentaires pour la préparation et l'utilisation de peptides de ciblage sélectifs et/ou spécifiques à la leucémie. Dans certains modes de réalisation, l'invention concerne des peptides de ciblage particuliers sélectifs ou spécifiques à des cellules de la leucémie, notamment mais pas exclusivement les SEQ ID NO: 5, SEQ ID NO: 6, ou SEQ ID NO: 7. D'autres modes de réalisation de cette invention concernent de tels peptides de ciblage fixés à des agents thérapeutiques. Dans d'autres modes de réalisation encore, des peptides de ciblage de la leucémie ou autre peuvent être utilisés pour administrer de façon sélective ou spécifique des agents thérapeutiques à des cellules cibles telles que des cellules de la leucémie. Dans d'autres modes de réalisation enfin, les procédés concernent l'identification, la préparation et l'utilisation de peptides de ciblage sélectifs ou spécifiques à une cellule, un tissu ou un organe cibles donnés tels que des cellules de la leucémie.
PCT/US2005/024414 2004-07-10 2005-07-11 Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie WO2006010070A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58681404P 2004-07-10 2004-07-10
US60/586,814 2004-07-10

Publications (2)

Publication Number Publication Date
WO2006010070A2 WO2006010070A2 (fr) 2006-01-26
WO2006010070A3 true WO2006010070A3 (fr) 2006-05-26

Family

ID=35785773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024414 WO2006010070A2 (fr) 2004-07-10 2005-07-11 Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie

Country Status (1)

Country Link
WO (1) WO2006010070A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781565B2 (en) * 2006-03-09 2010-08-24 The Board Of Regents Of The University Of Texas System Compositions and methods related to profiling a plurality of cells based on peptide binding
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
JP2010520238A (ja) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド 統合された光活性低分子および統合された光活性低分子使用
EP2178849A1 (fr) 2007-07-31 2010-04-28 Mallinckrodt Inc. Agents photoactifs intégrés et leurs utilisations
KR100968839B1 (ko) 2008-02-25 2010-07-09 경북대학교 산학협력단 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2011031955A2 (fr) * 2009-09-11 2011-03-17 Mallinckrodt Inc. Surveillance optique de la leucémie
WO2011084571A2 (fr) 2009-12-16 2011-07-14 Mallinckrodt Inc. Dérivés azides pour photothérapie
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2013038392A1 (fr) * 2011-09-18 2013-03-21 Ariel-University Research And Development Company, Ltd. Peptides capables de se lier aux cellules leucémiques b, conjugués, et compositions les contenant et leurs utilisations
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10702803B2 (en) 2016-11-01 2020-07-07 Northwestern University Layer-by-layer sorting of rhenium disulfide via high-density isopycnic density gradient ultracentrifugation
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US20030054375A1 (en) * 2000-01-31 2003-03-20 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US20030054375A1 (en) * 2000-01-31 2003-03-20 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Also Published As

Publication number Publication date
WO2006010070A2 (fr) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2006010070A3 (fr) Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie
EP2789628A3 (fr) Polypeptides de type aprotinine pour délivrer des agents conjugués à des tissus
WO2006004910A3 (fr) Anticorps bispecifiques ameliores
WO2009105671A3 (fr) Procédés et compositions liés aux peptides et aux protéines avec des éléments c-terminaux
EP2583976A3 (fr) Vaccins avec SEQ ID NO: 210, 196, 202, 213, 214, 214 ou 223 de peptide pour cancers exprimant des antigènes associés aux tumeurs
WO2007067682A3 (fr) Modification in vivo de surfaces cellulaires
WO2008079973A9 (fr) Peptides de liaison au récepteur egf et utilisations de ces derniers
WO2007044396A3 (fr) Polypeptides de fibronectine et methodes d'utilisation
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2008136869A3 (fr) Procédés et compositions relatives au ciblage de lésions, de tissu de régénération et de tumeurs
WO2008063291A3 (fr) Ligands polypeptidiques ciblant le cartilage et procédés d'utilisation de ceux-ci
WO2006124892A3 (fr) Modulateurs de la toxicite induite par l'alpha-synucleine
PL1791532T3 (pl) Kompozycja w mikropeletkach o kontrolowanym uwalnianiu substancji fizjologicznie czynnych, sposób jej wytwarzania i jej zastosowanie w dziedzinie zootechniki
WO2007035213A3 (fr) Ongules transgeniques exprimant la ctla4-ig et leurs utilisations
WO2006096774A3 (fr) Composition et methodes de diffusion de monoxyde de carbone (co) et de monoxyde d'azote (no) dans un tissu en utilisant des proteines heme comme supports
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
WO2009155556A3 (fr) Peptides de ciblage de crkl
WO2008033987A3 (fr) Compositions et procédés de prévention du cancer avec des cupredoxines
WO2007109648A3 (fr) Compositions et methodes de modulation d'entree calcique induite par reserve
WO2005030928A3 (fr) Proteine a chaine invariante porcine, adnc pleine longueur, organisation genomique et region regulatrice
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2005047469A3 (fr) Proteine isogloboside 3 synthase porcine, adnc, organisation genomique, et region regulatrice
GB0620255D0 (en) Antibody and uses thereof
MXPA05010575A (es) Peptacuerpo para el tratamiento del cancer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase